Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs

Cell chemical biology(2024)10.1016/j.chembiol.2024.03.008Source: DataRank Database

SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs is a research paper published in Cell chemical biology (2024). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

doi pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 13.86)OA: bronzeTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

David D. Ho ORCID,Sho Iketani ORCID

Live enrichment

PubMed:38640902 PMC:PMC11084874 OpenAlex:https://openalex.org/W4394935951

NIAID

Grant: 75N93021C00014

NIAID

Grant: 1U19AI171401

NIAID NIH HHS

Grant: U19 AI171401

Regeneron Pharmaceuticals

Shionogi

National Institutes of Health

FWCI

13.86

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S2451945624001247/pdf

HYBRIDhttps://www.cell.com/article/S2451945624001247/pdf

publisherhttp://www.cell.com/article/S2451945624001247/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2451945624001247?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451945624001247?httpAccept=text/plain

Fields of Study

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesViral gastroenteritis research and epidemiologyMedicineHumansSARS-CoV-2COVID-19Antibodies, MonoclonalPandemicsAntiviral Agents

MeSH Terms

COVID-19SARS-CoV-2Antibodies, MonoclonalAntiviral AgentsHumansPandemics

Keywords

Monoclonal antibodyPandemicCoronavirus disease 2019 (COVID-19)SurpriseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyResistance (ecology)Computational biologyBiologyMedicineAntibodyInfectious disease (medical specialty)ImmunologyDiseasePsychologyDrug resistanceAntiviralSmall-molecule InhibitorCovid-19Sars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being

SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs

FAIR Checklist

Authors (2)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)